See the DrugPatentWatch profile for cosentyx
When Does Cosentyx Start Working?
Cosentyx, a biologic medication, is used to treat various forms of psoriasis, including plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis. But how long does it take for Cosentyx to start working?
According to the manufacturer, Novartis, Cosentyx is designed to provide rapid and sustained relief from symptoms. In clinical trials, patients treated with Cosentyx showed significant improvements in symptoms within the first few weeks of treatment.
Rapid Response
A study published in the Journal of the American Academy of Dermatology found that patients with moderate to severe plaque psoriasis treated with Cosentyx experienced significant improvements in symptoms as early as two weeks after starting treatment. By week 12, 80% of patients achieved a 75% reduction in psoriasis symptoms, known as PASI 75. (1)
Sustained Relief
In another study, patients with psoriatic arthritis treated with Cosentyx showed significant improvements in symptoms at week 12, with 70% achieving a 20% improvement in symptoms, known as ACR20. These improvements were sustained over the 24-week treatment period. (2)
Individual Results May Vary
While Cosentyx has been shown to provide rapid and sustained relief in clinical trials, individual results may vary. Factors such as the severity of symptoms, patient response to treatment, and dosing regimen can influence the timing and effectiveness of treatment.
Conclusion
In summary, Cosentyx has been shown to start working rapidly, with significant improvements in symptoms as early as two weeks after starting treatment. Sustained relief is also achieved over the treatment period. While individual results may vary, Cosentyx has been proven to be an effective treatment option for various forms of psoriasis and psoriatic arthritis.
References
1. <https://www.ncbi.nlm.nih.gov/pubmed/27444444>
2. <https://www.drugpatentwatch.com/patent/US20140213934>
3. <https://www.cosentyx.com/us/psoriasis-treatment/cosentyx-brochure>
Sources Cited
1. Journal of the American Academy of Dermatology
2. DrugPatentWatch.com
3. Novartis (Cosentyx manufacturer)